The Astonea Labs Ltd IPO is an upcoming SME public issue scheduled to open on May 27, 2025, and close on May 29, 2025. The shares are set to be listed on the BSE SME platform on June 3, 2025.
Key Dates
- IPO Opens: May 27, 2025
- IPO Closes: May 29, 2025
- Allotment Finalization: May 30, 2025
- Refunds Initiated: June 2, 2025
- Shares Credited to Demat: June 2, 2025
- Listing Date: June 3, 2025
Astonea Labs Ltd IPO Overview
- Issue Type: Book Building (SME)
- Total Issue Size: ₹37.67 crore
- Price Band: ₹128 – ₹135 per share
- Face Value: ₹10 per share
- Lot Size: 1,000 shares
- Minimum Investment: ₹135,000 (at cap price)
- Total Shares Offered: 27.90 lakh
- Listing Exchange: BSE SME
- ISIN: INE0TG901011
- BSE Script Code: ASTONEALAB
Promoters of Astonea Labs Ltd
1) Ashish Gulati – Founder & Managing Director
Ashish Gulati is the visionary behind Astonea Labs Ltd., serving as its Founder and Managing Director. He holds a degree in Motorsport Engineering from Oxford Brookes University, UK, and completed his schooling at Hansraj Public School. Under his leadership, Astonea Labs has evolved into a significant player in the pharmaceutical and cosmeceutical manufacturing sectors, offering a diverse portfolio of over 1,700 SKUs.
2) Usha Gulati – Director
Usha Gulati is a Director at Astonea Labs Ltd. She has been associated with the company since its inception on April 11, 2017. Her experience includes serving as a Director and Whole-time Director at Shinto Organics Pvt. Ltd., indicating a strong background in the pharmaceutical industry.
3) Harsh Gulati – Director
Harsh Gulati also serves as a Director at Astonea Labs Ltd., with his appointment dating back to April 11, 2017. He brings extensive experience from his role as Managing Director at Shinto Organics Pvt. Ltd., contributing valuable industry insights to Astonea Labs.
Collectively, the Gulati family has been instrumental in steering Astonea Labs towards growth and innovation in the pharmaceutical and cosmeceutical sectors.
Astonea Labs Ltd IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Minimum) | 1 | 1000 | ₹1,35,000 |
| Retail (Maximum) | 1 | 1000 | ₹1,35,000 |
| HNI (Minimum) | 2 | 2,000 | ₹2,70,000 |
Retail investors can apply for a minimum of 1 lot (1,000 shares), amounting to ₹135,000 at the upper price band. For Non-Institutional Investors (NIIs), the minimum application is typically 2 lots, totaling 2,000 shares, which equates to ₹270,000 at the cap price.
Astonea Labs Ltd IPO Promoter Holding
As of the latest available information, the promoter holding details for Astonea Labs Ltd. are as follows:
| Shareholding | Percentage |
|---|---|
| Pre-Issue Holding | 98.42% |
| Post-Issue Holding | Not disclosed |
About Astonea Labs Ltd
Astonea Labs Ltd is a pharmaceutical and cosmeceutical manufacturing company headquartered in Panchkula, Haryana, India. Established in April 2017, the company specializes in contract development and manufacturing (CDMO) services, catering to both domestic and international clients.
With a legacy of over 35 years in the industry, Astonea Labs has evolved into a trusted partner for pharmaceutical and cosmeceutical solutions.
Company Overview
- Founded: April 11, 2017
- Founded: April 11, 2017
- Headquarters: Panchkula, Haryana, India
- Manufacturing Facility: Located in Village Haripur (Raipur Rani), Panchkula, spanning 20,000 square meters. The facility is designed to meet ISO standards and USFDA regulatory protocols, equipped with international machinery for production excellence.
- Certifications: WHO-GMP, ISO 9001, ISO 22000, CE, PETA, HALAL, ECO CERT.
Core Competencies:
- Manufacturing of pharmaceuticals, cosmetics, personal care, home care, innovative blended foods, drinks, effervescent products, Ayurveda, and other FMCG goods.
Product Portfolio
Astonea Labs offers a diverse range of products across various therapeutic areas, including:
- Pharmaceuticals: Antibiotics, antihistamines, antidiabetics, cardiovascular drugs, gynecological treatments, analgesics, antifungals, multivitamins.
- Cosmeceuticals: Skincare, dental, and hair care products in forms such as gels, ointments, creams, lotions, oils, and serums.
- Nutraceuticals and Herbal Products: Supplements and herbal formulations.
Astonea Labs Ltd Financial Information
Here is a comprehensive overview of Astonea Labs Ltd financial performance over the past three fiscal years, based on restated financials as per the company’s prospectus:
| Particulars | 2023-2024 | 2022-2023 | 2021-2022 |
|---|---|---|---|
| Revenue from Operations | ₹80.19 Crores | ₹67.05 Crores | ₹30.05 Crores |
| EBITDA | ₹11.71 Crores | ₹7.05 Crores | ₹5.65 Crores |
| Profit After Tax (PAT) | ₹3.80 Crores | ₹0.66 Crores | ₹0.24 Crores |
| Total Assets | ₹80.89 Crores | ₹64.27 Crores | ₹52.91 Crores |
| Net Worth | ₹11.96 Crores | ₹8.15 Crores | ₹7.49 Crores |
| Total Debt | ₹42.38 Crores | ₹35.98 Crores | ₹29.51 Crores |
Key Performance Indicator (KPI)
| Ratio | 2023-2024 | 2022-2023 | 2021-2022 |
|---|---|---|---|
| EBITDA Margin (%) | 14.60% | 10.51% | 18.80% |
| PAT Margin (%) | 4.74% | 0.98% | 0.80% |
| Earnings Per Share (EPS) | ₹5.01 | ₹0.88 | ₹0.33 |
| Return on Equity (ROE) | 31.77% | 8.10% | 3.20% |
| Return on Capital Employed (ROCE) | 22.95% | 10.83% | 6.02% |
| Return on Assets (ROA) | 4.70% | 1.03% | 0.45% |
| Debt-to-Equity Ratio | 3.54x | 4.41x | 3.94x |
Observations
- Revenue Growth: The company has shown a significant increase in revenue, growing from ₹30.05 crore in 2021-22 to ₹80.19 crore in 2023-24.
- Profitability: Profit After Tax (PAT) has improved markedly, rising from ₹0.24 crore in 2021-22 to ₹3.80 crore in 2023-24.
- Operational Efficiency: The EBITDA margin has increased from 10.51% in 2022-23 to 14.60% in 2023-24, indicating better operational efficiency.
- Leverage: The Debt-to-Equity ratio has decreased from 4.41x in 2022-23 to 3.54x in 2023-24, suggesting improved financial leverage.
Objects of the Issue
1) Registration in Bolivia and South America:
- The company plans to allocate ₹1.28 crore towards expenses related to obtaining necessary registrations in Bolivia and other South American countries. This strategic move is intended to facilitate the expansion of Astonea Labs’ market presence in these regions.
2) Purchase and Installation of Plant and Machinery:
- An amount of ₹5.23 crore is earmarked for the acquisition and installation of plant and machinery specifically for ointment production. This investment aims to enhance the company’s manufacturing capabilities to meet international standards and protocols, particularly for export purposes.
These allocations are designed to strengthen Astonea Labs Ltd.’s operational infrastructure and expand its global footprint, aligning with its long-term strategic objectives.
Strengths of Astonea Labs Ltd IPO
1) Diverse Product Portfolio
- Astonea Labs offers a wide range of products, including pharmaceuticals and cosmetics, across multiple dosage forms such as tablets, capsules, creams, gels, and serums.
2) State-of-the-Art Manufacturing Facility
- The company operates a modern manufacturing facility equipped with international machinery. The facility holds multiple quality certifications, including ISO 9001:2015, ISO 22000:2018, ISO 22716:2007, and HALAL, ensuring adherence to global quality standards.
3) Experienced Management Team
- With over six years of experience, the management team has demonstrated the ability to drive sustainable business growth and innovation, contributing to the company’s expansion in both domestic and international markets.
4) Scalable and Customer-Centric Business Model
- Astonea Labs follows a scalable, customer-centric, and order-driven business model, focusing on optimizing existing resources and ensuring timely delivery with minimal product rejection.
5) Growing International Presence
- The company exports its products to various international markets, including Iraq and Yemen, and plans to expand further by obtaining necessary registrations in South American countries like Bolivia.
Risks of Astonea Labs Ltd IPO
1) High Debt Levels
- As of March 31, 2024, Astonea Labs reported total borrowings of ₹42.40 crore. High debt levels can impact the company’s financial flexibility and may pose risks if not managed prudently.
2) Dependence on Contract Manufacturing
- A significant portion of the company’s revenue comes from contract manufacturing. Any loss of major clients or reduction in orders could adversely affect the company’s financial performance.
3) Regulatory Compliance and Approval Risks
- Operating in the pharmaceutical and cosmetic sectors requires strict adherence to regulatory standards. Delays or failures in obtaining necessary approvals, especially for international markets, could hinder expansion plans.
4) Competitive Industry Landscape
- The pharmaceutical and cosmetic industries are highly competitive, with numerous players offering similar products. Maintaining market share and profitability requires continuous innovation and effective marketing strategies.
5) SME IPO Volatility
- Being listed on the BSE SME platform, the company’s shares may experience higher volatility and lower liquidity compared to mainboard listings, potentially affecting investor exit options.
Conclusion:
Astonea Labs Ltd exhibits strong fundamentals, including a diverse product range, modern manufacturing capabilities, and an experienced management team. However, potential investors should carefully consider the associated risks, particularly the company’s debt levels and reliance on contract manufacturing. As with any investment, thorough due diligence and consultation with financial advisors are recommended.
Astonea Labs Ltd Contact Details
Here are the official contact details for Astonea Labs Ltd, including their registered office, headquarters, manufacturing facility, and key communication channels:
🏢 Registered Office
- Address: SCO 186-187, 2nd Floor, Cabin No. 206, Sector 8C, Chandigarh – 160009
- Phone: +91 9888302323
- Email: cs@astonea.org
- CIN: U24304CH2017PLC041482
🏭 Headquarters
- Address: SCO 331, Second Floor, Panchkula, Haryana – 134109
🏗️ Manufacturing Facility
📧 Departmental Contacts
- Domestic Sales: sales@astonea.org
- Export Sales: info@astonea.org
- Purchasing: purchase@astonea.org
- Public Relations: astoneapr@gmail.com
- Human Resources: hr@astonea.org
- Investor Grievances: investorgrievance@astonea.org
- Finance (CFO): financeastonea@gmail.com
🌐 Online Presence
- Official Website: www.astonea.org
- LinkedIn: Astonea Labs Limited
- Facebook: Astonea Labs Limited
Astonea Labs Ltd IPO Registrar
The registrar for the Astonea Labs Ltd IPO is KFin Technologies Limited, a prominent registrar and transfer agent in India. They are responsible for handling all aspects related to the IPO application process, allotment status, refunds, and investor grievances.
🏢 Registrar Details
- Name: KFin Technologies Limited
- Address: Selenium Building, Tower-B, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddi, Telangana – 500032
- Phone: +91 40 6716 2222
- Email: ipo@kfintech.com
- Investor Grievance Email: einward.ris@kfintech.com
- Website: www.kfintech.com
For any queries related to your IPO application, allotment status, or refunds, you can reach out to KFin Technologies through the contact details provided above. Additionally, you can check the allotment status and other IPO-related information on their official website.
Blue Water Logistics Limited IPO Review: Date, Price, & Details
Unified Data- Tech Solutions Limited IPO Details
Victory Electric Vehicles International Limited IPO Details
Disclaimer: The content on this website is intended for informational purposes only and should not be interpreted as financial or investment advice. Engaging in stock market activities involves inherent risks, and outcomes can be unpredictable. While we strive to provide accurate and up-to-date information, we do not make any guarantees regarding the completeness or reliability of the content. Any investment decisions you make should be based on your own research and consultation with a qualified financial professional. We are not responsible for any financial gains or losses resulting from actions taken based on the information provided here. Always invest wisely and at your own risk.
